arrow
L

Luis Alameda

Institute of Psychiatry
H指数:26
被引数:2,142

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Revisiting the link between childhood adversity and stress-sensitive brain regions in psychosis and bipolar disorder: a systematic review and meta-analysis

重新审视童年逆境与精神分裂症和双相障碍中应激敏感脑区之间的关联:一项系统综述和荟萃分析

2026-09-190
OAAI
Integrating biological pathway polygenic scores and trauma in psychosis: findings from the EU-GEI study

整合生物通路多基因评分与创伤在精神分裂症中的研究:EU-GEI研究的结果

2026-08-050
OA
Gene-Environment Correlation Across Trauma Subtypes and Developmental Timing: Evidence from EU-GEI and ALSPAC

创伤亚型与发育时间点上的基因-环境相关性:来自EU-GEI和ALSPAC的证据

2026-03-310
OAAI
The Long-Term Follow-Up TIPP Project: LOFT Study Protocol, a 20-Year Prospective Study of Early Psychosis Patients

长期随访TIPP项目:LOFT研究方案,一项对早期精神病患者进行的20年前瞻性研究

2026-01-010
OAAI
Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative

收集语言、语音声学和面部表情数据以预测精神分裂症及其他临床结果:AMP® SCZ倡议的策略

2025-10-150
OAAI
Relationships between adverse childhood experiences, oxidative stress, and development of mental disorders: A systematic review of animal and human studies

不良童年经历、氧化应激与精神障碍发展的关系:动物与人类研究的系统综述

2025-10-140
OAAI
Impact of maternal stress and COVID-19 exposure during pregnancy on offspring neurodevelopment: signature cohort 12 month follow-up

孕期母体压力和COVID-19暴露对子代神经发育的影响:标志性队列12个月随访

2025-09-100
OAAI
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

加速药品合作计划®精神分裂症项目中的脑电图协议:测量指标的可靠性与稳定性

2025-06-060
OAAI
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program

加速药物合作®精神分裂症计划中的数字健康技术

2025-06-030
OAAI
Pathways between childhood trauma, clinical symptoms, and functioning in new-onset psychosis: novel insights from a network analysis approach

儿童创伤、临床症状与新发精神病之间的影响路径:来自网络分析方法的全新见解

2025-05-150
OA